Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/26/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Andrew D. Redd

Wrong Dr. Andrew D. Redd?

Staff Scientist

Local Address: Washington D.C., District of Columbia, United States
National Institute of Allergy and Infectious Diseases
6610 Rockledge Dr. Room 4800
Bethesda , Maryland 20892
United States

Company Description: NIAID conducts and supports research-at NIH, throughout the United States, and worldwide-to study the causes of infectious and immune-mediated diseases, and to...   more
Background

Employment History

Board Memberships and Affiliations

13 Total References
Web References
The research was led by Andrew ...
www.positivelypositive.ca, 20 Sept 2012 [cached]
The research was led by Andrew D. Redd, Ph.D., staff scientist, and Thomas C. Quinn, M.D., senior investigator, both in the Laboratory of Immunoregulation of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
...
Dr. Redd and colleagues examined particular genetic sequences of HIV in blood samples collected between 1994 and 2002 from hundreds of HIV-infected heterosexuals participating in the Rakai Community Cohort Study in Rakai District, Uganda.
...
According to Dr. Redd, this finding demonstrates that in the heterosexual transmission of HIV, the frequent natural selection of viral strains from early in the infection of the transmitting partner reduces viral diversity at the population level.
Moreover, in four couples, the newly acquired strain was highly similar or identical to specific variants found in the transmitting partner at both the earliest time point and the time of transmission. The scientists hypothesize that these highly transmissible HIV strains from early infection were sustained in the blood at low levels or sequestered in certain cells for transmission at a later time.
Related research by other scientists shows that HIV strains found in infected individuals during the early stages of infection have diversified little from the strain that caused infection. Thus, the fact that these early HIV strains somehow are maintained or persist at low levels for transmission later suggests they may have an evolutionary advantage at crossing the genital barrier and causing infection, compared with HIV strains that predominate later in infection, according to Dr. Redd.
...
Anthony S. Fauci, M.D., NIAID director and chief of the NIAID Laboratory of Immunoregulation; and Andrew D. Redd, Ph.D., staff scientist in the NIAID Laboratory of Immunoregulation, are available for comment.
The study, published online in the ...
www.whatabouthiv.org, 18 June 2012 [cached]
The study, published online in the Journal of Infectious Diseases, was led by Thomas C. Quinn, M.D., and Andrew D. Redd, Ph.D., of NIAID's Laboratory of Immunoregulation, and Maria J. Wawer, M.D., Ph.D., formerly of the Columbia University Mailman School of Public Health, New York City, and now with Johns Hopkins University Bloomberg School of Public Health, Baltimore.
...
"Previous studies of HIV superinfection have focused on individuals exposed to the virus through high-risk sexual activity or intravenous drug use," said lead author Dr. Redd.
...
"Our findings suggest that HIV vaccine strategies designed to recreate the natural immune response to HIV may be insufficient to protect an individual from infection," Dr. Redd noted.
Rutger Hauer Starfish Association
www.rutgerhauer.org, 12 June 2012 [cached]
Dr. Andrew Redd said there are HIV infections and then there are superinfections.
"A superinfection occurs when an individual is initially infected with a strain or strains of HIV. And then at some point later on - after that person has developed an initial immune response to their first infecting strain - at that later time point they come into contact through risky behavior with a second viral strain and then are superinfected with that second strain," he said.
Redd is the lead author of the study and a scientist at the National Institute of Allergy and Infectious Diseases. He said prior to the research done in Uganda it was thought that superinfections were rare, occurring in intravenous drug users or men who have sex with men. Not so.
"What we found in our study was that when we looked at a general population of heterosexual individuals in Uganda we found that it actually isn't as rare as what we thought. And that it is occurring at a significant rate even in the general population," he said.
...
And in Uganda, we have subtype A and subtype D," said Redd.
...
Redd says, though, that standard antiretroviral treatment should be effective against superinfections. "We have no evidence so far and we don't think that HIV superinfection affects the response to treatment. From what we can tell, individuals who get superinfected respond to treatment just fine and it lowers their viral load and they get healthier.
One of the things that we're worried about, though, if the possibility that an individual could get superinfected with a viral strain that is already resistant to the antiretroviral drugs and that would be a major problem.
But to date that doesn't seem to be a huge risk so far," said Redd.
...
Redd added that current HIV vaccine strategies that try to "recreate the natural immune response may be insufficient to protect an individual from infection."
Dr. Andrew Redd said there are ...
www.voanews.com [cached]
Dr. Andrew Redd said there are HIV infections and then there are superinfections.
"A superinfection occurs when an individual is initially infected with a strain or strains of HIV. And then at some point later on - after that person has developed an initial immune response to their first infecting strain - at that later time point they come into contact through risky behavior with a second viral strain and then are superinfected with that second strain," he said.
Redd is the lead author of the study and a scientist at the National Institute of Allergy and Infectious Diseases. He said prior to the research done in Uganda it was thought that superinfections were rare, occurring in intravenous drug users or men who have sex with men. Not so.
"What we found in our study was that when we looked at a general population of heterosexual individuals in Uganda we found that it actually isn't as rare as what we thought. And that it is occurring at a significant rate even in the general population," he said.
...
And in Uganda, we have subtype A and subtype D," said Redd.
...
Redd says, though, that standard antiretroviral treatment should be effective against superinfections.
"We have no evidence so far and we don't think that HIV superinfection affects the response to treatment. From what we can tell, individuals who get superinfected respond to treatment just fine and it lowers their viral load and they get healthier. One of the things that we're worried about, though, if the possibility that an individual could get superinfected with a viral strain that is already resistant to the antiretroviral drugs and that would be a major problem. But to date that doesn't seem to be a huge risk so far," said Redd.
...
Redd added that current HIV vaccine strategies that try to "recreate the natural immune response may be insufficient to protect an individual from infection."
Andrew Redd of the ...
www.hivandhepatitis.net, 13 Mar 2012 [cached]
Andrew Redd of the National Institute of Allergies and Infectious Diseases collaborated with the researchers conducting the well-studied Rakai Cohort in Uganda to perform so-called ultra-deep sequencing, next-generation genetic tests on blood samples collected at different times from people with HIV.
Other People with the name "Redd":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304